NCT04322617 2024-06-04
ATHENA
Hunan Province Tumor Hospital
Phase 2/3 Recruiting
Clinical Trials
3 trialsNCT02388919 2017-09-18
ALTER0303
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed
NCT02029209 2016-12-16
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown